Browsing Biochemistry and Microbial Sciences-Research Publications by Author "Ali, Villayat"
Now showing items 1-5 of 5
-
Aldose Reductase: a cause and a potential target for the treatment of diabetic complications
Thakur, Sapna; Gupta, Sonu Kumar; Ali, Villayat; Singh, Priyanka; Verma, Malkhey (Pharmaceutical Society of Korea, 2021-07-19)Diabetes mellitus, a disorder of metabolism, results in the elevation of glucose level in the blood. In this hyperglycaemic condition, aldose reductase overexpresses and leads to further complications of diabetes through ... -
Alterations in cellular metabolisms after Imatinib therapy: a review
Kumar, Veerandra; Singh, Priyanka; Gupta, Sonu Kumar; Ali, Villayat; Jyotirmayee; Verma, Malkhey (Springer, 2022-05-16)Chronic myeloid leukemia (CML) is characterized by the possession of the Philadelphia chromosome, which contains the Bcr-Abl oncogene that codes for the oncoprotein BCR-ABL. Through glucose metabolism, glycolysis, and the ... -
Metabolic flux analysis in plant metabolic network
Ali, Villayat; Singh, Priyanka; Gupta, Sonu; Vijaykumar; Mauley, Yogesh; Verma, Malkhey (2018) -
miR-145-5p and miR-203a-5p overcome imatinib resistance in myelogenous leukemic cells through metabolic reprogramming
Singh, Priyanka; Gupta, Sonu Kumar; Ali, Villayat; Chhabra, Ravindresh; Verma, Malkhey (National Institute of Science Communication and Policy Research, 2023-03-01)Imatinib is the most effective therapy for chronic myeloid leukemia (CML), but many patients eventually develop resistance to it after an initial satisfactory response. This study investigated the potential of three miRNAs ... -
Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review
Kumar, Veerandra; Singh, Priyanka; Gupta, Sonu Kumar; Ali, Villayat; Verma, Malkhey (Springer, 2022-02-07)Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a specific pharmacological profile. Asciminib has ...